PO BOX 2544 


© 2019 Ryan's Quest       501(c) (3)Documentation

(609) 947-3611

February 24, 2017

SEATTLE, Feb. 24 2017 /PRNewswire/ -- DMD Therapeutics, Inc., a start-up biotech company, is developing proprietary therapeutics for Duchenne muscular dystrophy (DMD), an orphan disease associated with serious morbidity and early mortality that has a major unmet need. The Company's first drug candidate, DMD-813, has been shown to reduce damage and inflammation in muscle leading to markedly increased muscle strength in the stan...

Please reload

Please reload

Recent Posts
Search By Tags